Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Bank of America
Keros Therapeutics (NASDAQ:KROS – Get Free Report) was downgraded by Bank of America from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, Marketbeat reports. They currently have a $18.00 price target on the stock, down from their prior price target of $32.00. Bank of America‘s […]
Keros Therapeutics (NASDAQ:KROS – Get Free Report) was downgraded by Bank of America from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, Marketbeat reports. They currently have a $18.00 price target on the stock, down from their prior price target of $32.00. Bank of America‘s […]
